How Much Does a Gastric Balloon Cost? The Out-of-Pocket Price and Value

A gastric balloon in the United States typically costs about $6,000–$9,000, and here is the part the clinic brochures bury: it is almost always paid entirely out of pocket, because most insurers still classify the intragastric balloon as investigational and do not cover it. That price buys a temporary, 6-month device — the balloon is placed, left in for roughly half a year, then removed — after which meaningful weight regain is common. So the honest way to think about the cost is not the sticker price but the cost per durably kept-off pound, and on that measure the balloon is the weakest value of the mainstream weight-loss options. The device delivers roughly 11.3% total body weight loss (TBWL) at 12 months, peaking near 13.2% at 6 months while it is in place^[1] — less than endoscopic sleeve gastroplasty (~13.6%, lasting years^[3]) and less than a GLP-1 (semaglutide ~14.9%^[6]; tirzepatide ~20.9%^[7]) — and it carries a genuine FDA safety signal, including death reports^[8]. This article breaks down what the price includes, why insurance almost never pays, how financing works, and why the 6-month cap plus regain make the value case hard to defend.

The honest summary

• The core answer: about $6,000–$9,000, out of pocket. In the US market a gastric balloon is typically quoted in the $6,000–$9,000 range, all-in, and is almost never covered by insurance because most payers treat it as investigational. (That is a current US market range, not a trial-derived figure.)
• You are paying a large sum for a 6-month device. The balloon is placed, indwells for about 6 months, then is endoscopically removed. Nothing about your anatomy is permanently changed, so the cost buys a temporary effect, not a lasting one.
• Regain after removal makes the value worse. Weight loss peaks at 6 months (~13.2% TBWL) and partly reverses after the balloon comes out^[1]. The number that matters — cost per pound you actually keep off — is therefore worse than the sticker price suggests.
• It is the worst cost-per-durable-pound of the options. ESG costs more up front (roughly $8,000–$20,000 by the price ranges in the table below), but its weight loss has held for years in follow-up studies^[3][5]; a GLP-1 costs monthly but keeps working while you take it^[6][7]. The balloon is a big one-time bill for the shortest-lived result.
• The FDA safety history is part of the value equation. The FDA reported 18 deaths worldwide (8 in the US) since the Orbera and ReShape balloons were approved in 2015, plus gastric perforation, acute pancreatitis, and spontaneous hyperinflation^[8]. A device you pay full price for and that carries this risk profile has to clear a high bar.
• Financing exists, but does not change the math. Many clinics offer payment plans or medical-credit financing; spreading $6,000–$9,000 over 12–24 months lowers the monthly hit but adds interest and does not improve the underlying cost-per-kept-off-pound.
• Its honest niche is a paid short-term jump-start — not a durable, cost-efficient answer. For lasting value, most people are better served by a GLP-1 or ESG; see the balloon vs GLP-1 head-to-head.

What the $6,000-$9,000 actually includes

A gastric balloon program is usually sold as a bundled package price rather than an itemized medical bill, and that bundle is where the $6,000–$9,000 comes from. What is typically folded into the quote:

• The device itself — the balloon (Orbera, ReShape, Obalon, or Spatz3) and any single-use placement hardware.
• Placement and removal. Most balloons are placed endoscopically under light sedation in about 20–30 minutes, and the endoscopic removal at ~6 months is normally part of the same package — two procedures, one price.
• Anesthesia and facility fees for both the placement and the removal.
• A support program. Reputable programs bundle in dietitian visits, coaching, or a structured behavior-change plan for the 6 months the balloon is in — which is the part that actually determines whether any of the loss survives removal.

Why insurance almost never pays

This is the single biggest driver of the balloon's cost problem: you are almost always paying the whole thing yourself. Most US insurers still classify the intragastric balloon as investigational or not medically necessary, so — unlike surgical bariatric procedures, which are frequently covered when documented medical criteria are met — the balloon rarely qualifies for coverage. That flips the usual drug-versus-procedure math. A GLP-1 may be partly covered by insurance but costs money every month indefinitely; the balloon is a large, mostly un-reimbursed one-time cost. For how coverage works on the procedures that are often paid for, see what insurance covers and how much weight-loss surgery costs.

The value problem: a large price for a temporary device

Cost only means something next to what you get for it. The balloon's efficacy is real but modest and, critically, time-limited. In the ASGE PIVI meta-analysis^[1], the Orbera balloon produced about 25.4% excess weight loss and ~11.3% TBWL at 12 months, peaking near 13.2% TBWL at 6 months while the device is in place. Notice the shape of that curve: weight loss peaks at 6 months and then partly reverses as the balloon comes out and appetite returns. The headline number is a peak, not a plateau. Real-world results typically land in the 7–15% TBWL range, and the durable, kept-off figure is lower still once regain is counted.

That is why the sticker price undersells the true cost. If you pay $7,500 and lose weight that largely returns over the year after removal, the cost per pound you actually keep can be poor. The balloon does not alter anatomy the way a surgical or endoscopic sleeve does, so once it is out, holding the loss depends entirely on sustained behavior change — which you could pursue without paying for a device at all.

Cost vs the alternatives: what your money buys

Here is the honest cross-comparison. No trial has pitted these against each other on cost or efficacy, so the weight-loss figures are cross-trial and directional. The point of the table is the durability-adjusted value: what the spend actually buys and for how long.

• Versus ESG: ESG can cost more up front, but its restriction lasts years^[3][5], so the durability-adjusted cost per kept-off pound is far better. Paying nearly balloon money for a 6-month effect versus a multi-year one is the crux of the value case — see what ESG costs.
• Versus a GLP-1: a drug is a recurring bill, but it keeps working as long as you take it^[6][7] and is often at least partly insured, whereas the balloon is a large un-reimbursed one-time cost for a capped 6-month result.
• Versus surgery: surgical sleeve or bypass is frequently insurance-covered and produces the largest, most durable loss (~25–30%) — making the fully self-paid, temporary balloon a hard sell on pure value.
• The one thing the balloon buys that the others don't: speed and simplicity — a one-time, ~20-minute placement with no daily or weekly medication. If that specific benefit is what you are paying for, the price can make sense; for durable results, it usually does not.

For the full drug-versus-device argument, see our dedicated gastric balloon vs GLP-1 comparison and the broader endoscopic weight-loss options overview.

Prefer a monthly GLP-1 to a large one-time device cost? Top vetted providers

Financing, and why it doesn't fix the value case

Because the balloon is paid out of pocket, most clinics offer some way to spread the cost — in-house payment plans, third-party medical-credit lines, or CareCredit-style financing. Spreading $6,000–$9,000 over 12–24 months turns a single large bill into a manageable monthly figure, which is genuinely useful for cash flow. But financing changes when you pay, not what you get:

• Interest adds to the total. Unless it is a true 0% promotional plan you pay off in the window, financing makes the balloon cost more, not less.
• The device life doesn't stretch to match the loan. If you finance over 24 months, you may still be paying for the balloon a year after it has already been removed — and after any regain has set in.
• It doesn't improve cost-per-kept-off-pound. The underlying value problem — a large cost for a temporary result — is unchanged by how you schedule the payments.

When the cost can still make sense

• You specifically want a short-term, one-time jump-start — to build early momentum or lose weight ahead of another procedure — and you accept the effect ends when the balloon comes out^[1].
• You cannot take, tolerate, or access a GLP-1 long-term and want a non-drug, defined-period intervention, with eyes open to the cost and the 6-month cap.
• You will pair it with real behavior change — because the balloon's biggest weakness is regain, the plan for after removal is what protects the money you spent.
• You value the simplicity of a single ~20-minute placement with no ongoing medication enough to pay a premium for it.

Who it is not good value for: anyone seeking durable, larger, more cost-efficient weight loss. A GLP-1, ESG, or covered surgery will almost always deliver more kept-off weight per dollar over a realistic horizon.

Bottom line

• A gastric balloon in the US typically costs about $6,000–$9,000, almost always out of pocket, because insurers generally classify it as investigational. (US market range, not a trial figure.)
• That price buys a temporary 6-month device delivering ~11–13% TBWL at its peak^[1], with regain common after removal — so the cost-per-durably-kept-off-pound is the worst of the mainstream options.
• ESG costs more up front but lasts years^[3][5]; a GLP-1 is a monthly, often part-insured bill that keeps working while you take it^[6][7] — both are better durability-adjusted value.
• Financing spreads the payment but adds interest and doesn't fix the value math, and the FDA safety signal (18 deaths worldwide, 8 in the US, plus perforation, pancreatitis, hyperinflation^[8]) is a real part of the cost-versus-benefit calculus.
• The balloon's honest niche is a paid short-term jump-start; for durable, cost-efficient results, see the balloon vs GLP-1 head-to-head.

Cost figures are current US market ranges and vary by clinic, device, and region; they are not trial-derived, and no dollar amount here is a citation-backed clinical measurement. An intragastric balloon is an invasive device with real risks, including the FDA-reported deaths, gastric perforation, acute pancreatitis, and spontaneous hyperinflation described above; suitability and cost must be assessed with a qualified bariatric endoscopist. Cross-trial comparisons with GLP-1 drugs, ESG, and surgery are not head-to-head and should be interpreted with care. Do not start, stop, or change any treatment based on this article.